標(biāo)題: Titlebook: Anticancer Drug Development Guide; Preclinical Screenin Beverly A. Teicher Book 1997 Springer Science+Business Media New York 1997 cancer.c [打印本頁] 作者: papyrus 時間: 2025-3-21 16:29
書目名稱Anticancer Drug Development Guide影響因子(影響力)
書目名稱Anticancer Drug Development Guide影響因子(影響力)學(xué)科排名
書目名稱Anticancer Drug Development Guide網(wǎng)絡(luò)公開度
書目名稱Anticancer Drug Development Guide網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Anticancer Drug Development Guide被引頻次
書目名稱Anticancer Drug Development Guide被引頻次學(xué)科排名
書目名稱Anticancer Drug Development Guide年度引用
書目名稱Anticancer Drug Development Guide年度引用學(xué)科排名
書目名稱Anticancer Drug Development Guide讀者反饋
書目名稱Anticancer Drug Development Guide讀者反饋學(xué)科排名
作者: figure 時間: 2025-3-21 21:25 作者: Conquest 時間: 2025-3-22 01:53 作者: 阻擋 時間: 2025-3-22 07:43 作者: 失望昨天 時間: 2025-3-22 12:37 作者: 平息 時間: 2025-3-22 16:09 作者: STALE 時間: 2025-3-22 18:38 作者: Omniscient 時間: 2025-3-23 00:33
https://doi.org/10.1007/978-3-658-07520-0have been summarized recently (.). Test procedures are designed to provide comparative quantitative data, which in turn, permit selection of the best candidate agents from a given chemical or biological class. Periodic, comprehensive reviews by various NCI committees serve not only to identify and e作者: 必死 時間: 2025-3-23 04:39 作者: 我沒有強(qiáng)迫 時間: 2025-3-23 08:01 作者: 新手 時間: 2025-3-23 13:16
https://doi.org/10.1007/978-3-662-00830-0 been in leukemia, lymphoma, and selected solid tumors, such as testis cancer. The administration of very high doses of chemotherapy requiring hematopoietic stem-cell support has had more than a 10-year history (.). Even with this heroic treatment, cure of solid tumors, such as breast cancer and sma作者: 滲透 時間: 2025-3-23 17:50
https://doi.org/10.1007/978-3-642-49816-9erapies. The majority of this work has been performed on inbred rodent models and laboratoryderived canine populations. Working with inbred populations in controlled, artificial laboratory environments raises some degree of concern over the applicability of information as it relates to naturally occ作者: Enervate 時間: 2025-3-23 18:02
Betriebs- und Wirtschaftsinformatiknters (DCTDC). The Developmental Therapeutics Program (DTP) of DCTDC promotes all aspects of the discovery and preclinical development of new compounds as drugs. Its activities include demonstration of antiproliferative activity in vitro through its 60 human tumor cell line screen and in vivo using 作者: 野蠻 時間: 2025-3-23 22:34
https://doi.org/10.1007/978-3-642-71759-8rmamentarium of cancer therapeutics. Hence, the design, implementation, and analyses of a Phase I study must be viewed with a critical eye, acknowledging the limitations of this approach in determining the ultimate fate of a new agent. The overall objectives, design, and methodology of the clinical 作者: NATAL 時間: 2025-3-24 04:03 作者: 姑姑在炫耀 時間: 2025-3-24 08:03 作者: LAP 時間: 2025-3-24 13:43 作者: 富饒 時間: 2025-3-24 16:13 作者: filial 時間: 2025-3-24 19:23 作者: 名詞 時間: 2025-3-24 23:25
In Vivo Methods for Screening and Preclinical TestingThe classic question in the field of drug discovery is: Which tumor model is a satis-factory predictor for cancer in humans? The classic answer is: None of them!作者: obstinate 時間: 2025-3-25 06:48 作者: instructive 時間: 2025-3-25 11:18
https://doi.org/10.1007/978-1-4615-8152-9cancer; cancer research; clinical trial; drug; drug development; drug discovery; leukemia; methodology; rese作者: 商業(yè)上 時間: 2025-3-25 12:35
978-1-4615-8154-3Springer Science+Business Media New York 1997作者: 合適 時間: 2025-3-25 17:33
Anticancer Drug Development Guide978-1-4615-8152-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: Lime石灰 時間: 2025-3-25 22:50
,Bestimmte Integrale über ebene Gebiete,an important role in drug evaluation, but with the development of a large number of cytotoxic drugs, animal models are too costly and the delay is too long for these models to be used for large-scale screening.作者: 受人支配 時間: 2025-3-26 01:25
Textbook‘‘‘‘‘‘‘‘ 2021Latest editionobjective of this chapter is to describe the role of the US Food and Drug Administration (FDA) in the development process and to discuss the requirements for approval of new cancer drugs. The new drug development process is illustrated in Fig. 1.作者: LAP 時間: 2025-3-26 06:30 作者: RENIN 時間: 2025-3-26 09:33 作者: brachial-plexus 時間: 2025-3-26 16:22
Drug Development in Europeized in 1938 (.). This incidentally was one of the first examples of a collaborative clinical trial. The Royal Society of Medicine in the UK obtained an undertaking from a dozen centers to enter at least 10 patients each, within 1 yr. The combined results showed quite clearly that responses in breas作者: inspiration 時間: 2025-3-26 18:15
2196-9906 volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.978-1-4615-8154-3978-1-4615-8152-9Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: Overstate 時間: 2025-3-26 23:19 作者: 倫理學(xué) 時間: 2025-3-27 04:35
Betriebs- und Wirtschaftsinformatikcal trial groups, or as part of the activities of Phase I and II cooperative agreement organizations. CTEP also monitors the conduct of these studies as well as Phase III studies focusing on the optimal use of currently available FDA-approved agents.作者: cipher 時間: 2025-3-27 06:51 作者: 藝術(shù) 時間: 2025-3-27 11:24
High-Volume Screeningan important role in drug evaluation, but with the development of a large number of cytotoxic drugs, animal models are too costly and the delay is too long for these models to be used for large-scale screening.作者: 課程 時間: 2025-3-27 15:55 作者: Obstacle 時間: 2025-3-27 20:52 作者: 我的巨大 時間: 2025-3-28 00:54 作者: sterilization 時間: 2025-3-28 03:35
Human Tumor Xenograft Models in NCI Drug Developmenthave been summarized recently (.). Test procedures are designed to provide comparative quantitative data, which in turn, permit selection of the best candidate agents from a given chemical or biological class. Periodic, comprehensive reviews by various NCI committees serve not only to identify and e作者: 窩轉(zhuǎn)脊椎動物 時間: 2025-3-28 09:55
Fertile Seed and Rich Soilf cancer to test and investigate the hypothesis of Paget, as well as for treatment discovery. Thus, there has been a critical need in cancer treatment and research for rodent models that are clinically relevant. Ideal models would allow the transplantation of the majority of human tumors, such that 作者: Thyroxine 時間: 2025-3-28 12:21 作者: Host142 時間: 2025-3-28 17:13
Models for Minimal Residual Tumor been in leukemia, lymphoma, and selected solid tumors, such as testis cancer. The administration of very high doses of chemotherapy requiring hematopoietic stem-cell support has had more than a 10-year history (.). Even with this heroic treatment, cure of solid tumors, such as breast cancer and sma作者: 小樣他閑聊 時間: 2025-3-28 21:21
Spontaneously Occurring Tumors in Companion Animals as Models for Drug Developmenterapies. The majority of this work has been performed on inbred rodent models and laboratoryderived canine populations. Working with inbred populations in controlled, artificial laboratory environments raises some degree of concern over the applicability of information as it relates to naturally occ作者: 本土 時間: 2025-3-28 23:26
Working with the National Cancer Institutenters (DCTDC). The Developmental Therapeutics Program (DTP) of DCTDC promotes all aspects of the discovery and preclinical development of new compounds as drugs. Its activities include demonstration of antiproliferative activity in vitro through its 60 human tumor cell line screen and in vivo using 作者: Needlework 時間: 2025-3-29 06:01
Phase I Trial Design and Methodologyrmamentarium of cancer therapeutics. Hence, the design, implementation, and analyses of a Phase I study must be viewed with a critical eye, acknowledging the limitations of this approach in determining the ultimate fate of a new agent. The overall objectives, design, and methodology of the clinical 作者: 別名 時間: 2025-3-29 07:27 作者: CARK 時間: 2025-3-29 11:42
Drug Development in Europe potassium arsenite (Fowlers solution) given systemically was reported to have dramatic, although transient, effects on leukemias and lymphomas in the mid-19th century (.). One of the early “breakthroughs” came from studies in the UK on synthetic estrogens, which in the 1930s had been shown to inhib作者: 拔出 時間: 2025-3-29 15:49
FDA Role in Cancer Drug Development and Requirements for Approvalobjective of this chapter is to describe the role of the US Food and Drug Administration (FDA) in the development process and to discuss the requirements for approval of new cancer drugs. The new drug development process is illustrated in Fig. 1.作者: 慷慨援助 時間: 2025-3-29 20:20 作者: 一再困擾 時間: 2025-3-30 01:56
,Funktionen mehrerer Ver?nderlicher,the tumor would behave in the rodent in a similar manner as it did in the patient. Such models would be useful for the individual patient treatment design and for evaluation of new antineoplastic agents and procedures.作者: 痛打 時間: 2025-3-30 05:54
Human Tumor Xenograft Models in NCI Drug Developmentxpedite the development of active lead compounds that may provide more efficacious treatments for human malignancy, but also to eliminate agents that are inactive and/or highly toxic from further consideration.作者: 鬼魂 時間: 2025-3-30 10:03
Fertile Seed and Rich Soilthe tumor would behave in the rodent in a similar manner as it did in the patient. Such models would be useful for the individual patient treatment design and for evaluation of new antineoplastic agents and procedures.作者: 逃避責(zé)任 時間: 2025-3-30 15:35
Book 1997itor (Cancer Therapeutics: Experimental and Clinical Agents) reviews existing anticancer drugs and potential anticancer therapies. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.作者: constitutional 時間: 2025-3-30 19:26
2196-9906 arduous process of cancer drug discovery and approval. They focus on using preclinical in vivo and in vitro methods to identify molecules of interest, detailing the targets and criteria for success in each type of testing and defining the value of the information obtained from the various tests. The作者: 刺穿 時間: 2025-3-31 00:34 作者: NIB 時間: 2025-3-31 01:27 作者: uveitis 時間: 2025-3-31 06:04 作者: 結(jié)構(gòu) 時間: 2025-3-31 09:59
Murine L1210 and P388 Leukemiastly reduced level. This chapter reviews their past and present roles in the evaluation of anticancer drugs. Data for the sensitivity of these two leukemias and the drug-resistant P388 sublines to clinically useful drugs are reported.作者: PALL 時間: 2025-3-31 17:18
Phase I Trial Design and Methodologying the limitations of this approach in determining the ultimate fate of a new agent. The overall objectives, design, and methodology of the clinical Phase I study will be reviewed in this chapter with an emphasis on potential innovative approaches to streamline and improve the current design and practice of such trials.作者: Bridle 時間: 2025-3-31 18:20
Phase II Clinical Trials in Oncologyatment protocol. By specifying in this document the target group of patients, the treatment conditions, and the desired criteria of success or failure, potential sources of bias are minimized. The treatment evaluation is thus based on objective results rather than deductive reasoning (.).作者: 果核 時間: 2025-4-1 00:41
Grenzwerte und stetige Funktionen,I for further evaluation in other tumor models or alternative screens. Most of the available clinical anticancer agents are active in the P388 system; however, most were discovered prior to 1975 or by observations initially in test systems other than the NCI-operated P388 primary screen.作者: 憤怒事實(shí) 時間: 2025-4-1 05:19
